Carbonic anhydrase (CA, E.C.4.2.1.1), an enzyme puri-fied from erythrocytes for the first time in 19931, plays an important role in mammals, in processes such as pH control, gas balance, ion transport, calcification, secretion of electrolytes, and tumourigenesis among others2. CAs, of which many diverse isoforms are currently known, effectively catalyze a slow, but fundamental physiological reaction, the conversion of carbon dioxide to bicarbonate and protons3,4. CAs are classified in five distinct classes, the α, β, γ, δ and ζ families5. These types of CAs are pres-ent in different organisms, but the α-CAs are the only such enzymes found in mammals. The β-class is mainly found in plants, fungi and prokaryotes; γ-CAs were iden-tified in Archaea and some bacteria6. The ε-CA class was
reclassified as a different type of β-CA based on crystal-lographic data7,8, which showed a nearly identical fold to those of the canonical, archaeal (cab-type) and plant-type (Pisum sativum) β-CAs9–11. In ζ-CA, the geometry of the active site is nearly identical to that of β-CAs, and there is also some similarity in the protein fold, but these enzymes contain Cd(II) at their active site, not Zn (II) as the other genetic CA families6, although they function also with Zn(II) or Co(II) replacing the cadmium ion.
In mammals, 16 different CA isoenzymes have been described so far2. Some of these isozymes are cytosolic (CA I, CA II, CA III, CA VII and CA XIII), others are mem-brane bound (CA IV, CA IX, CA XII and CA XIV), two are mitochondrial (CA VA and CA VB) and one is secreted in saliva and milk (CA VI12). Human and most mammalian
RESEARCH ARTICLE
Inhibition of carbonic anhydrase isozymes I and II with natural products extracted from plants, mushrooms and honey
Huseyin Sahin1, Zehra Can1, Oktay Yildiz1, Sevgi Kolayli1, Alessio Innocenti2, Gabriele Scozzafava,3 and Claudiu T. Supuran2
1Karadeniz Technique University, Department of Chemistry, Trabzon, Turkey, 2Università degli Studi di Firenze, Polo Scientifico, Laboratorio di Chimica Bioinorganica, Rm. 188, Via della Lastruccia 3, Sesto Fiorentino, Florence, Italy, and 3Università degli Studi di Firenze, Dipartimento di Economia, Ingegneria, Scienze e Tecnologie Agrarie e Forestali (D.E.I.S.T.A.F.), Firenze, Italy
AbstractDifferent natural products and secondary metabolites from mushrooms, teas, honeys, mosses, plants and seaweeds were investigated for their in vitro inhibitory effects on human carbonic anhydrase (hCA, E.C.4.2.1.1) isoforms I and II. Inhibition data were correlated with the total phenol content in the extract and investigated with the pure compounds believed to be responsible for this activity. Methanolic extracts were prepared for 17 such pure chemicals present in the natural products and for 41 diverse natural products. The IC50 values were in the range of 0.11–66.50 μg/mL against hCA I and of 0.09–54.54 μg/mL against hCA II, respectively. The total phenol content was in the range of 0.02–1318.96 (as milligrams of gallic acid equivalents) per gram of sample. These data offer new insights on possible novel classes of CA inhibitors based on natural products, possessing a range of chemical structures not present in the classical inhibitors with pharmacological applications, such as the sulfonamides and sulfamates.Keywords: Carbonic anhydrase, natural products, phenol, inhibition, isoform I and II
Address for Correspondence: Huseyin Sahin, Karadeniz Technique University, Department of Chemistry, Trabzon, Turkey. Tel.: +90 462 377 36 64, Fax: +90 462 325 31. E-mail: [email protected], or Claudiu T. Supuran, Università degli Studi di Firenze, Polo Scientifico, Laboratorio di Chimica Bioinorganica, Rm. 188, Via della Lastruccia 3, Sesto Fiorentino, Florence, Italy. Tel.: +39-055–4573005, Fax: +39-055–4573385. E-mail: [email protected]
(Received 11 May 2011; revised 28 May 2011; accepted 30 May 2011)
Journal of Enzyme Inhibition and Medicinal Chemistry
red blood cells comprise two CA isozymes, CA I (slow enzyme of low catalytic efficiency) and human CA (hCA II; rapid, highly effective catalysts for the CO
2 hydration
reaction13). hCA I and hCA II are two of the most abun-dant protein (after hemoglobin) in human erythrocytes.
The catalytic mechanism of CAs is understood in detail. In all enzyme classes, a metal hydroxide species of the enzyme is the catalytically active species, acting as a strong nucleophile on the CO
2 molecule bound in a
hydrophobic pocket nearby2. This metal hydroxide spe-cies is generated from water coordinated to the metal ion, which is found at the bottom of the active site cav-ity. The active centre normally comprises M (II) ions in tetrahedral geometry, with three protein ligands (L) in addition to the water molecule/hydroxide ion, but Zn(II) and Co(II) were also observed in trigonal bipyramidal or octahedral coordination geometries2,14–18.
The inhibition of CA is a well understood process, with most (but not all) classes of inhibitors binding to the metal centre19–29. Inhibition can be achieved by four different mechanisms. First, coordination of the inhibi-tor to the Zn(II) ion by replacing the zinc-bound water/hydroxide ion, leading to a tetrahedral geometry of Zn(II). Second mechanism is addition of the inhibitor to the metal coordination sphere, when the Zn(II) ion is in a trigonal bipyramidal geometry12,30. Third type of inhibi-tion consists of the anchoring of the inhibitor molecule to the Zn (II)-bound solvent molecule, a water or hydroxide ion31. The fourth type of inhibition is achieved by occlu-sion of the entrance to the active site cavity, when the inhibitors bind in the activator binding region32–36. Many CA inhibitors were synthesized and evaluated in the last decades, whereas natural product compounds started to be investigated only recently37. For this reason, the pri-mary objective of this study was the screening of in vitro inhibitory effects on the cytosolic, widely spread iso-forms hCA I and hCA II of some natural product extracts and the corresponding pure chemicals species present in them. Most of these compounds are known to possess antioxidant effects.
Materials and methods
ReagentsAnalytical grade methanol was obtained from Merck Co. (Merck, Darmstadt, Germany). Buffers and other reagents were of the highest purity grade, from Sigma-Aldrich (Milan, Italy). CA isozymes were recombinant ones obtained as reported earlier. Folin-Ciocalteu’s phe-nol reagent was from Fluka Chemie GmbH (Switzerland). Polytetrafluoroethylene membranes (porosity 0.2 μm) for the filtration of the extracts were obtained from Sartorius (Goettingen, Germany).
Samples and preparation of extractsAll samples were prepared in methanol. Because chemi-cals can be dissolved completely in methanol, an extrac-tion process was not used. The natural products were
continuously stirred with a shaker at 60°C for 24 h. The suspension was removed by filtration then centrifuged at 10,000g for 15 min. The supernatant was concentrated in a rotary evaporator under reduced pressure, and the residue resolved in a minimal volume of the same sol-vent and kept in 4°C until use.
CA catalytic activity and inhibitionAn Applied Photophysics stopped-flow instrument has been used for assaying the CA catalysed CO
2 hydration
activity. Phenol red (at a concentration of 0.2 mM) has been used as an indicator, working at the absorbance maximum of 557 nm, with 20 mM HEPES (pH 7.5) as buf-fers and 20 mM Na
2SO
4 (for maintaining constant ionic
strength), following the initial rates of the CA-catalysed CO
2 hydration reaction for a period of 10–100 s. The CO
2
concentrations ranged from 1.7 to 17 mM for the deter-mination of the kinetic parameters and inhibition con-stants. For each sample, at least six traces of the initial 5–10% of the reaction have been used for determining the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. Solutions of extracts (10 mM) were prepared in dis-tilled, deionized water and diluted up to 0.01 nM thereaf-ter with distilled, deionized water. Inhibitory sample and enzyme solutions were preincubated together for 15 min at room temperature before assay to allow for the forma-tion of the enzyme–inhibitor complex. The IC
50 represents
the concentration of inhibitor producing a 50% decrease of the catalytic rate and was obtained by nonlinear least-squares methods using PRISM 3 and represent the mean from at least three different determinations.
Determination of total phenolicsTotal phenolic (TP) content was determined by the Folin-Ciocalteu procedure38 using gallic acid as standard. In brief, 20 μL of various concentrations of gallic acid and samples (20 μL), 400 μL of 0.5 N Folin-Ciocalteu reagent and 680 μL of distilled water was added, and the con-tents were vortexed. After 3 min incubation, 400 μL of Na
2CO
3 (10%) solution was added, and after vortexing,
the mixture was incubated for 2 h at 25°C with intermit-tent shaking. The absorbance was measured at 760 nm at the end of the incubation period. The concentration of TP compounds was calculated as milligrams of gallic acid equivalents (GAE) per gram of 100 g FW, by using a standard graph for gallic acid in the concentration range between 0.015 and 0.5 mg/mL (r2 = 0.9997).
Statistic analysisResults ate presented as mean values of two replicates. Data and regression analyses were tested using SPSS for Windows Release 10 (SPSS Inc.).
Results and discussion
Many natural products are rich in phenolic com-pounds and possess antioxidant, antibacterial,
Jour
nal o
f E
nzym
e In
hibi
tion
and
Med
icin
al C
hem
istr
y D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y D
r C
laud
iu T
. Sup
uran
on
04/3
0/12
For
pers
onal
use
onl
y.
Inhibition of carbonic anhydrase isozymes I and II 397
anti-inflammatory, antiallergic and antithrombotic activities37,39,40. As far as we know, such products have never been tested for their inhibitory activities against the CA family of enzymes. Indeed, CA inhibitors, especially aromatic and heterocyclic sulfonamides, have been and are used clinically for more than 50 years in the treatment of a variety of diseases such as glaucoma, epilepsy, obesity, mountain sickness, gas-tric and duodenal ulcers, osteoporosis and acid–base disequilibria2. Recently, some sulfonamide CA inhibi-tors were demonstrated to possess relevant antitumour and antimetastatic effects41,42.
We have prepared some pure chemical standards and natural compounds, most of which are aromatic derivatives based on the flavone core structure, various substituted phenols/polyphenols and phenolic aromatic acids as methanolic extracts and measured their TP con-tent (Tables 1 and 2). Total phenols were expressed in milligrams of gallic acid per gram of sample. Especially, rhamnetin, protocatechuic acid and catechin extracts
showed higher phenolic content than other prepara-tions. It may be observed that in the chemical samples, the total polyphenol contents were between 0.76 ± 0.37
Journal of Enzyme Inhibition and Medicinal Chemistry
and 1318.96 ± 1.00 mgGAE/g of sample, whereas for the mushrooms 0.57 ± 0.05 and 3.49 ± 0.35, teas 59.71 ± 1.27 and 602.92 ± 1.09, honeys 0.20 ± 0.01 and 0.90 ± 0.05, natural compounds 0.05 ± 0.01 and 37.58 ± 0.01 mgGAE/g sample (Table 2).
We measured thereafter the inhibitory effects of these samples against the purified cytosolic CA iso-forms hCA I and II, which are among the physiologically most relevant such enzymes2. The inhibition results are expressed as IC
50 and were found to be in the range of
0.11–66.50 μg/mL for hCA I and 0.09–54.54 μg/mL for hCA II (Table 2). The meaning of IC
50 is the concentration
of compound (molarity or in this specific case, expressed in mg/mL) that reduces the CA activity by 50%. Among all the investigated samples, it may be observed that the extraction method highly influenced the CA inhibitory activity against both isoforms. Because the components are pure chemicals belonging to the polyphenol class, they are expected to show some inhibition against hCA I and II, and phenols are highly investigated as CA inhibi-tors37. Rhamnetin showed the highest value of total poly-phenol content, according to the gallic acid standard, and it was also a potent inhibitor of hCA I and II. trans-Cinnamic acid (C17) was the best inhibitor, with IC
50 val-
ues of 0.11–0.09 μg/mL (Table 2). It should be mentioned that 2-hydroxy-trans-cinnamic acid was recently discov-ered to be a CA inhibitor, being formed from coumarin (a prodrug) by active-site–mediated hydrolysis33,34. This compound binds in a particular manner to the enzyme, at the entrance of the active site cavity, as shown by X-ray crystallography. Coumarins also led to highly isoform-selective CA inhibitors33,34, and one such compound has notable antitumour and antimetastatic properties, being in preclinical evaluation as an anticancer drug41.
White tea is prepared from young tea leaves or buds covered with tiny, silvery hairs, which are harvested only once a year in the early spring. It is richer in phe-nolic compounds, especially catechin and its derivatives, compared with mature tea43. Pleurotus eryngii contains various phenolic components especially catechin, simi-lar to white tea44. Because of the high catechin content, white tea (T3), among the tea species and P. eryngii (M3) among the mushrooms, showed the lowest IC
50 and
highest total polyphenol value among the investigated extracts (Table 2).
Different honey types contain diverse components that have antioxidant, antimicrobial, antiviral, and anti-fungal effects, by mechanisms not well elucidated yet45–47. Chestnut honey is one type of honey known for its excel-lent properties. Küçük et al.45 reported that chestnut honey contains superior amounts of the total polyphenols (which are responsible for the antioxidant effects) com-pared with rhododendron and flower honeys. Chestnut honey (H5) investigated here showed the best value on hCA I and II inhibition among the various honeys.
Phenolic compounds were investigated in Mentha piperita by Areias et al.48 According to this study, M. piperita contains a high percentage of phenolic
compounds such as eriodictyol, luteolin, hesperetin, apigenin, and rosmarinic acid, etc.48 These compounds might be responsible for the inhibition of hCA I and II observed in the current study, but this hypothesis must be verified.
Marine algae are potentially prolific sources of highly bioactive secondary metabolites that might represent useful leads in the development of new pharmaceutical agents49. According to Chewa et al.50, Padina pavonica contains a high amount of polyphenols50. However, our results show that the value of TP compounds is similar to each other among all investigated seaweeds (Table 2). This also may explain the CA inhibition effects of the algal extracts, which were similar to each other (Table 2).
In conclusion, we report that a CA I and II inhibition study with natural product compounds that contain polyphenols and flavones, extracted from various plants, mushrooms and honey. Many of these rather effective inhibitors detected here can be used as lead compounds for developing novel classes of CA inhibitors, presum-ably with a new mechanism of inhibition, which may be similar to that of the coumarins, newly discovered class of inhibitors of these enzymes.
Acknowledgments
We also thank Assoc. Prof. Dr. Turan ÖZDEMIR for providing and identifying the moss sample Biology Department, Karadeniz Technical University, and also thanks to Assoc. Prof. Dr. Ömer ERTÜRK for pro-viding and identifying the seaweeds sample Biology Department, Ordu University. Work from Supuran lab was financed by two FP7 EU projects (Metoxia and Gums and Joints).
Declaration of interest
This study was supported by Research Fund of Karadeniz Technical University (Project No: 2009.111.002.5). One of the authors (H. Sahin) would like to thank TUBİTAK, BİDEB, TURKEY, for the financial support given to him.
References1. Meldrum NU, Roughton FJ. Carbonic anhydrase. Its preparation
applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–181.
3. Sahin H, Aliyazicioglu R, Yildiz O, Kolayli S, Innocenti A, Supuran CT. Honey, polen, and propolis extracts show potent inhibitory activity against the zinc metalloenzyme carbonic anhydrase. J Enzyme Inhib Med Chem 2011;26:440–444.
4. Tripp BC, Smith K, Ferry JG. Carbonic anhydrase: new insights for an ancient enzyme. J Biol Chem 2001;276:48615–48618.
5. Elleuche S, Pöggeler S. Carbonic anhydrases in fungi. Microbiology (Reading, Engl) 2010;156:23–29.
6. Xu Y, Feng L, Jeffrey PD, Shi Y, Morel FM. Structure and metal exchange in the cadmium carbonic anhydrase of marine diatoms. Nature 2008;452:56–61.
Jour
nal o
f E
nzym
e In
hibi
tion
and
Med
icin
al C
hem
istr
y D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y D
r C
laud
iu T
. Sup
uran
on
04/3
0/12
For
pers
onal
use
onl
y.
Inhibition of carbonic anhydrase isozymes I and II 401
7. So AK, Espie GS, Williams EB, Shively JM, Heinhorst S, Cannon GC. A novel evolutionary lineage of carbonic anhydrase (epsilon class) is a component of the carboxysome shell. J Bacteriol 2004;186:623–630.
8. Sawaya MR, Cannon GC, Heinhorst S, Tanaka S, Williams EB, Yeates TO et al. The structure of beta-carbonic anhydrase from the carboxysomal shell reveals a distinct subclass with one active site for the price of two. J Biol Chem 2006;281:7546–7555.
9. Strop P, Smith KS, Iverson TM, Ferry JG, Rees DC. Crystal structure of the “cab”-type beta class carbonic anhydrase from the archaeon Methanobacterium thermoautotrophicum. J Biol Chem 2001;276:10299–10305.
10. Kimber MS, Pai EF. The active site architecture of Pisum sativum beta-carbonic anhydrase is a mirror image of that of alpha-carbonic anhydrases. Embo J 2000;19:1407–1418.
11. Syrjänen L, Tolvanen M, Hilvo M, Olatubosun A, Innocenti A, Scozzafava A et al. Characterization of the first beta-class carbonic anhydrase from an arthropod (Drosophila melanogaster) and phylogenetic analysis of beta-class carbonic anhydrases in invertebrates. BMC Biochem 2010;11:28.
12. Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010;20:3467–3474.
13. Supuran CT. Carbonic anhydrase inhibition/activation: trip of a scientist around the world in the search of novel chemotypes and drug targets. Curr Pharm Des 2010;16:3233–3245.
14. Supuran CT. Carbonic Anhydrases as Drug Targets—General Presentation. In Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications; Supuran, C. T., Winum, J. Y., Eds.; Wiley: Hoboken, NJ, 2009, pp 15–38;
15. Winum JY, Rami M, Scozzafava A, Montero JL, Supuran C. Carbonic anhydrase IX: a new druggable target for the design of antitumor agents. Med Res Rev 2008;28:445–463.
16. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146–189.
17. Domsic JF, Avvaru BS, Kim CU, Gruner SM, Agbandje-McKenna M, Silverman DN et al. Entrapment of carbon dioxide in the active site of carbonic anhydrase II. J Biol Chem 2008;283:30766–30771.
18. Supuran CT, Scozzafava A. Carbonic anhydrases as targets for medicinal chemistry. Bioorg Med Chem 2007;15:4336–4350.
19. Supuran CT. Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. Curr Pharm Des 2008;14:641–648.
20. Supuran CT, Di Fiore A, De Simone G. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2008;13:383–392.
21. De Simone G, Di Fiore A, Supuran CT. Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? Curr Pharm Des 2008;14:655–660.
22. Temperini C, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. X-ray crystal studies of the carbonic anhydrase II-trithiocarbonate adduct–an inhibitor mimicking the sulfonamide and urea binding to the enzyme. Bioorg Med Chem Lett 2010;20:474–478.
23. Krungkrai J, Supuran CT. The alpha-carbonic anhydrase from the malaria parasite and its inhibition. Curr Pharm Des 2008;14:631–640.
24. Borras J, Scozzafava A, Menabuoni L, Mincione F, Briganti F, Mincione G et al. Carbonic anhydrase inhibitors: synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamides containing 8-quinoline-sulfonyl moieties: is the tail more important than the ring? Bioorg Med Chem 1999;7:2397–2406.
25. Nishimori I, Onishi S, Takeuchi H, Supuran CT. The alpha and beta classes carbonic anhydrases from Helicobacter pylori as novel drug targets. Curr Pharm Des 2008;14:622–630.
26. Schlicker C, Hall RA, Vullo D, Middelhaufe S, Gertz M, Supuran CT et al. Structure and inhibition of the CO2-sensing carbonic anhydrase Can2 from the pathogenic fungus Cryptococcus neoformans. J Mol Biol 2009;385:1207–1220.
27. Isik S, Kockar F, Aydin M, Arslan O, Guler OO, Innocenti A et al. Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates. Bioorg Med Chem 2009;17:1158–1163.
28. Carta F, Maresca A, Covarrubias AS, Mowbray SL, Jones TA, Supuran CT. Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c. Bioorg Med Chem Lett 2009;19:6649–6654.
29. Kolaylı S, Karahalil F, Sahin H, Dincer B, Supuran CT. Characterization and inhibition studies of an alpha carbonic anhydrase from the endangered sturgeon species Acipenser gueldenstaedti. J Enzyme Inhib Med Chem 2010. (doi: 10.3109/14756366.2011.554415)
30. Alterio V, Hilvo M, Di Fiore A, Supuran CT, Pan P, Parkkila S et al. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc Natl Acad Sci USA 2009;106:16233–16238.
31. Nair SK, Ludwig PA, Christianson DW. Two-site binding of phenol in the active site of human carbonic anhydrase II: structural implications for substrate association. J Am Chem Soc 1994;116:3659–3660.
32. Vu H, Pham NB, Quinn RJ. Direct screening of natural product extracts using mass spectrometry. J Biomol Screen 2008;13:265–275.
33. Maresca A, Temperini C, Vu H, Pham NB, Poulsen SA, Scozzafava A et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009;131:3057–3062.
34. Maresca A, Temperini C, Pochet L, Masereel B, Scozzafava A, Supuran CT. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem 2010;53:335–344.
35. Temperini C, Innocenti A, Scozzafava A, Parkkila S, Supuran CT. The coumarin-binding site in carbonic anhydrase accommodates structurally diverse inhibitors: the antiepileptic lacosamide as an example and lead molecule for novel classes of carbonic anhydrase inhibitors. J Med Chem 2010;53:850–854.
36. Innocenti A, Durdagi S, Doostdar N, Strom TA, Barron AR, Supuran CT. Nanoscale enzyme inhibitors: fullerenes inhibit carbonic anhydrase by occluding the active site entrance. Bioorg Med Chem 2010;18:2822–2828.
37. Supuran CT. Carbonic anhydrase inhibition with natural products: novel chemotypes and inhibition mechanisms. Mol Divers 2011;15:305–316.
38. Singleton VL, Rossi JL. Colorimetry of total phenolics with phosphomolybdic phosphotungstic acid reagents. Am J Enol Vitic 1965;16:144–158.
39. Owen RW, Giacosa A, Hull WE, Haubner R, Spiegelhalder B, Bartsch H. The antioxidant/anticancer potential of phenolic compounds isolated from olive oil. Eur J Cancer 2000;36:1235–1247.
40. Rodriguez Vaguero MJ, Tomassini Serravalle LR, Manca de Nadra MC, Strasser de Saad AM. Antioxidant capacity and antibacterial activity of phenolic compounds from argentinean herbs infusions. Food Control 2010;21:779–785.
41. Pacchiano F, Carta F, McDonald PC, Lou Y, Vullo D, Scozzafava A et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem 2011;54:1896–1902.
42. Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A et al. Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors. Cancer Res 2011;71:3364–3376.
43. Rusak G, Komes D, Likić S, Horžić D, Kovač M. Phenolic content and antioxidative capacity of green and white tea extracts depending on extraction conditions and the solvent used. Food Chem 2008;110:852–858.
44. Oke F, Aslim B. Protective effect of two edible mushrooms against oxidative cell damage and their phenolic composition. Food Chem 2011. doi:10.1016/j.foodchem.2011.03.03.
Jour
nal o
f E
nzym
e In
hibi
tion
and
Med
icin
al C
hem
istr
y D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y D
r C
laud
iu T
. Sup
uran
on
04/3
0/12
For
pers
onal
use
onl
y.
402 H. Sahin et al
Journal of Enzyme Inhibition and Medicinal Chemistry
45. Küçük M, Kolaylı S, Karaoğlu Ş,, Ulusoy E, Baltacı C, Candan F. Biological activities and chemical composition of three honeys of different types from Anatolia. Food Chem 2007;100:526–534.
46. Gomes S, Dias LG, Moreira LL, Rodrigues P, Estevinho L. Physicochemical, microbiological and antimicrobial properties of commercial honeys from Portugal. Food Chem Toxicol 2010;48:544–548.
47. Alvarez-Suarez JM, Tulipani S, Díaz D, Estevez Y, Romandini S, Giampieri F et al. Antioxidant and antimicrobial capacity of several monofloral Cuban honeys and their correlation with color,
polyphenol content and other chemical compounds. Food Chem Toxicol 2010;48:2490–2499.
![4-[N-(Substituted 4-pyrimidinyl)amino]benzenesulfonamides as inhibitors of carbonic anhydrase isozymes I, II, VII, and XIII](https://static.documents.pub/doc/80x56/6344b08ddf19c083b107b61a/4-n-substituted-4-pyrimidinylaminobenzenesulfonamides-as-inhibitors-of-carbonic.jpg)
